Research ArticleArticle
Longterm Drug Survival of Tumor Necrosis Factor Inhibitors in Patients with Rheumatoid Arthritis
Paul Emery, Bonnie Vlahos, Piotr Szczypa, Mazhar Thakur, Heather E. Jones, John Woolcott, Paul V. Santos Estrella, Catherine Rolland, Allan Gibofsky, Gustavo Citera, Sargunan Sockalingam and Lisa Marshall
The Journal of Rheumatology June 2019, jrheum.181398; DOI: https://doi.org/10.3899/jrheum.181398
Paul Emery
From the Leeds Institute of Rheumatic and Musculoskeletal Medicine, and Leeds National Institute for Health Research (NIHR) Biomedical Research Centre, The Leeds Teaching Hospitals Trust, Leeds, UK. The systematic literature review to support this manuscript was sponsored by Pfizer. PE declares consultancy fees from AbbVie, Bristol-Myers Squibb, Eli Lilly & Co., and Novartis. BV, PS, MT, HEJ, JW, PVSE, and LM are employees of Pfizer, or were employees of Pfizer when this study was conducted, and hold stock or stock options with Pfizer. AG holds stock in AbbVie, Amgen, Celgene, GSK, Johnson & Johnson, Pfizer, and Regeneron, and declares consultancy fees from AbbVie, Celgene, Merck & Co., and Pfizer, and has served on a speakers’ bureau for AbbVie, Celgene, Flexion, Merck & Co., Novartis, and Pfizer. CR is an employee of Envision Pharma Group and was a paid consultant to Pfizer in connection with the development of the systematic literature review. GC declares consultancy fees from Bristol-Myers Squibb and Pfizer. P. Emery, FMedSci, Leeds Institute of Rheumatic and Musculoskeletal Medicine, and Leeds NIHR Biomedical Research Centre, The Leeds Teaching Hospitals Trust; B. Vlahos, MBA, Pfizer Inc.; P. Szczypa, MD, Pfizer Ltd.; M. Thakur, MD, Pfizer Ltd.; H.E. Jones, RN, Pfizer Inc.; J. Woolcott, PhD, Pfizer Inc.; P.V. Santos Estrella, MD, Pfizer Inc.; C. Rolland, PhD, Envision Pharma Group; A. Gibofsky, MD, Weill Medical College; G. Citera, MD, Instituto de Rehabilitación Psicofísica de Buenos Aires; S. Sockalingam, MMed, University Malaya Medical Centre; L. Marshall, PhD, Pfizer Inc. Address correspondence to P. Emery, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Chapel Allerton Hospital, Leeds LS7 4SA, UK. E-mail: p.emery@leeds.ac.uk. Accepted for publication May 17, 2019.
Bonnie Vlahos
From the Leeds Institute of Rheumatic and Musculoskeletal Medicine, and Leeds National Institute for Health Research (NIHR) Biomedical Research Centre, The Leeds Teaching Hospitals Trust, Leeds, UK. The systematic literature review to support this manuscript was sponsored by Pfizer. PE declares consultancy fees from AbbVie, Bristol-Myers Squibb, Eli Lilly & Co., and Novartis. BV, PS, MT, HEJ, JW, PVSE, and LM are employees of Pfizer, or were employees of Pfizer when this study was conducted, and hold stock or stock options with Pfizer. AG holds stock in AbbVie, Amgen, Celgene, GSK, Johnson & Johnson, Pfizer, and Regeneron, and declares consultancy fees from AbbVie, Celgene, Merck & Co., and Pfizer, and has served on a speakers’ bureau for AbbVie, Celgene, Flexion, Merck & Co., Novartis, and Pfizer. CR is an employee of Envision Pharma Group and was a paid consultant to Pfizer in connection with the development of the systematic literature review. GC declares consultancy fees from Bristol-Myers Squibb and Pfizer. P. Emery, FMedSci, Leeds Institute of Rheumatic and Musculoskeletal Medicine, and Leeds NIHR Biomedical Research Centre, The Leeds Teaching Hospitals Trust; B. Vlahos, MBA, Pfizer Inc.; P. Szczypa, MD, Pfizer Ltd.; M. Thakur, MD, Pfizer Ltd.; H.E. Jones, RN, Pfizer Inc.; J. Woolcott, PhD, Pfizer Inc.; P.V. Santos Estrella, MD, Pfizer Inc.; C. Rolland, PhD, Envision Pharma Group; A. Gibofsky, MD, Weill Medical College; G. Citera, MD, Instituto de Rehabilitación Psicofísica de Buenos Aires; S. Sockalingam, MMed, University Malaya Medical Centre; L. Marshall, PhD, Pfizer Inc. Address correspondence to P. Emery, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Chapel Allerton Hospital, Leeds LS7 4SA, UK. E-mail: p.emery@leeds.ac.uk. Accepted for publication May 17, 2019.
Piotr Szczypa
From the Leeds Institute of Rheumatic and Musculoskeletal Medicine, and Leeds National Institute for Health Research (NIHR) Biomedical Research Centre, The Leeds Teaching Hospitals Trust, Leeds, UK. The systematic literature review to support this manuscript was sponsored by Pfizer. PE declares consultancy fees from AbbVie, Bristol-Myers Squibb, Eli Lilly & Co., and Novartis. BV, PS, MT, HEJ, JW, PVSE, and LM are employees of Pfizer, or were employees of Pfizer when this study was conducted, and hold stock or stock options with Pfizer. AG holds stock in AbbVie, Amgen, Celgene, GSK, Johnson & Johnson, Pfizer, and Regeneron, and declares consultancy fees from AbbVie, Celgene, Merck & Co., and Pfizer, and has served on a speakers’ bureau for AbbVie, Celgene, Flexion, Merck & Co., Novartis, and Pfizer. CR is an employee of Envision Pharma Group and was a paid consultant to Pfizer in connection with the development of the systematic literature review. GC declares consultancy fees from Bristol-Myers Squibb and Pfizer. P. Emery, FMedSci, Leeds Institute of Rheumatic and Musculoskeletal Medicine, and Leeds NIHR Biomedical Research Centre, The Leeds Teaching Hospitals Trust; B. Vlahos, MBA, Pfizer Inc.; P. Szczypa, MD, Pfizer Ltd.; M. Thakur, MD, Pfizer Ltd.; H.E. Jones, RN, Pfizer Inc.; J. Woolcott, PhD, Pfizer Inc.; P.V. Santos Estrella, MD, Pfizer Inc.; C. Rolland, PhD, Envision Pharma Group; A. Gibofsky, MD, Weill Medical College; G. Citera, MD, Instituto de Rehabilitación Psicofísica de Buenos Aires; S. Sockalingam, MMed, University Malaya Medical Centre; L. Marshall, PhD, Pfizer Inc. Address correspondence to P. Emery, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Chapel Allerton Hospital, Leeds LS7 4SA, UK. E-mail: p.emery@leeds.ac.uk. Accepted for publication May 17, 2019.
Mazhar Thakur
From the Leeds Institute of Rheumatic and Musculoskeletal Medicine, and Leeds National Institute for Health Research (NIHR) Biomedical Research Centre, The Leeds Teaching Hospitals Trust, Leeds, UK. The systematic literature review to support this manuscript was sponsored by Pfizer. PE declares consultancy fees from AbbVie, Bristol-Myers Squibb, Eli Lilly & Co., and Novartis. BV, PS, MT, HEJ, JW, PVSE, and LM are employees of Pfizer, or were employees of Pfizer when this study was conducted, and hold stock or stock options with Pfizer. AG holds stock in AbbVie, Amgen, Celgene, GSK, Johnson & Johnson, Pfizer, and Regeneron, and declares consultancy fees from AbbVie, Celgene, Merck & Co., and Pfizer, and has served on a speakers’ bureau for AbbVie, Celgene, Flexion, Merck & Co., Novartis, and Pfizer. CR is an employee of Envision Pharma Group and was a paid consultant to Pfizer in connection with the development of the systematic literature review. GC declares consultancy fees from Bristol-Myers Squibb and Pfizer. P. Emery, FMedSci, Leeds Institute of Rheumatic and Musculoskeletal Medicine, and Leeds NIHR Biomedical Research Centre, The Leeds Teaching Hospitals Trust; B. Vlahos, MBA, Pfizer Inc.; P. Szczypa, MD, Pfizer Ltd.; M. Thakur, MD, Pfizer Ltd.; H.E. Jones, RN, Pfizer Inc.; J. Woolcott, PhD, Pfizer Inc.; P.V. Santos Estrella, MD, Pfizer Inc.; C. Rolland, PhD, Envision Pharma Group; A. Gibofsky, MD, Weill Medical College; G. Citera, MD, Instituto de Rehabilitación Psicofísica de Buenos Aires; S. Sockalingam, MMed, University Malaya Medical Centre; L. Marshall, PhD, Pfizer Inc. Address correspondence to P. Emery, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Chapel Allerton Hospital, Leeds LS7 4SA, UK. E-mail: p.emery@leeds.ac.uk. Accepted for publication May 17, 2019.
Heather E. Jones
From the Leeds Institute of Rheumatic and Musculoskeletal Medicine, and Leeds National Institute for Health Research (NIHR) Biomedical Research Centre, The Leeds Teaching Hospitals Trust, Leeds, UK. The systematic literature review to support this manuscript was sponsored by Pfizer. PE declares consultancy fees from AbbVie, Bristol-Myers Squibb, Eli Lilly & Co., and Novartis. BV, PS, MT, HEJ, JW, PVSE, and LM are employees of Pfizer, or were employees of Pfizer when this study was conducted, and hold stock or stock options with Pfizer. AG holds stock in AbbVie, Amgen, Celgene, GSK, Johnson & Johnson, Pfizer, and Regeneron, and declares consultancy fees from AbbVie, Celgene, Merck & Co., and Pfizer, and has served on a speakers’ bureau for AbbVie, Celgene, Flexion, Merck & Co., Novartis, and Pfizer. CR is an employee of Envision Pharma Group and was a paid consultant to Pfizer in connection with the development of the systematic literature review. GC declares consultancy fees from Bristol-Myers Squibb and Pfizer. P. Emery, FMedSci, Leeds Institute of Rheumatic and Musculoskeletal Medicine, and Leeds NIHR Biomedical Research Centre, The Leeds Teaching Hospitals Trust; B. Vlahos, MBA, Pfizer Inc.; P. Szczypa, MD, Pfizer Ltd.; M. Thakur, MD, Pfizer Ltd.; H.E. Jones, RN, Pfizer Inc.; J. Woolcott, PhD, Pfizer Inc.; P.V. Santos Estrella, MD, Pfizer Inc.; C. Rolland, PhD, Envision Pharma Group; A. Gibofsky, MD, Weill Medical College; G. Citera, MD, Instituto de Rehabilitación Psicofísica de Buenos Aires; S. Sockalingam, MMed, University Malaya Medical Centre; L. Marshall, PhD, Pfizer Inc. Address correspondence to P. Emery, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Chapel Allerton Hospital, Leeds LS7 4SA, UK. E-mail: p.emery@leeds.ac.uk. Accepted for publication May 17, 2019.
John Woolcott
From the Leeds Institute of Rheumatic and Musculoskeletal Medicine, and Leeds National Institute for Health Research (NIHR) Biomedical Research Centre, The Leeds Teaching Hospitals Trust, Leeds, UK. The systematic literature review to support this manuscript was sponsored by Pfizer. PE declares consultancy fees from AbbVie, Bristol-Myers Squibb, Eli Lilly & Co., and Novartis. BV, PS, MT, HEJ, JW, PVSE, and LM are employees of Pfizer, or were employees of Pfizer when this study was conducted, and hold stock or stock options with Pfizer. AG holds stock in AbbVie, Amgen, Celgene, GSK, Johnson & Johnson, Pfizer, and Regeneron, and declares consultancy fees from AbbVie, Celgene, Merck & Co., and Pfizer, and has served on a speakers’ bureau for AbbVie, Celgene, Flexion, Merck & Co., Novartis, and Pfizer. CR is an employee of Envision Pharma Group and was a paid consultant to Pfizer in connection with the development of the systematic literature review. GC declares consultancy fees from Bristol-Myers Squibb and Pfizer. P. Emery, FMedSci, Leeds Institute of Rheumatic and Musculoskeletal Medicine, and Leeds NIHR Biomedical Research Centre, The Leeds Teaching Hospitals Trust; B. Vlahos, MBA, Pfizer Inc.; P. Szczypa, MD, Pfizer Ltd.; M. Thakur, MD, Pfizer Ltd.; H.E. Jones, RN, Pfizer Inc.; J. Woolcott, PhD, Pfizer Inc.; P.V. Santos Estrella, MD, Pfizer Inc.; C. Rolland, PhD, Envision Pharma Group; A. Gibofsky, MD, Weill Medical College; G. Citera, MD, Instituto de Rehabilitación Psicofísica de Buenos Aires; S. Sockalingam, MMed, University Malaya Medical Centre; L. Marshall, PhD, Pfizer Inc. Address correspondence to P. Emery, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Chapel Allerton Hospital, Leeds LS7 4SA, UK. E-mail: p.emery@leeds.ac.uk. Accepted for publication May 17, 2019.
Paul V. Santos Estrella
From the Leeds Institute of Rheumatic and Musculoskeletal Medicine, and Leeds National Institute for Health Research (NIHR) Biomedical Research Centre, The Leeds Teaching Hospitals Trust, Leeds, UK. The systematic literature review to support this manuscript was sponsored by Pfizer. PE declares consultancy fees from AbbVie, Bristol-Myers Squibb, Eli Lilly & Co., and Novartis. BV, PS, MT, HEJ, JW, PVSE, and LM are employees of Pfizer, or were employees of Pfizer when this study was conducted, and hold stock or stock options with Pfizer. AG holds stock in AbbVie, Amgen, Celgene, GSK, Johnson & Johnson, Pfizer, and Regeneron, and declares consultancy fees from AbbVie, Celgene, Merck & Co., and Pfizer, and has served on a speakers’ bureau for AbbVie, Celgene, Flexion, Merck & Co., Novartis, and Pfizer. CR is an employee of Envision Pharma Group and was a paid consultant to Pfizer in connection with the development of the systematic literature review. GC declares consultancy fees from Bristol-Myers Squibb and Pfizer. P. Emery, FMedSci, Leeds Institute of Rheumatic and Musculoskeletal Medicine, and Leeds NIHR Biomedical Research Centre, The Leeds Teaching Hospitals Trust; B. Vlahos, MBA, Pfizer Inc.; P. Szczypa, MD, Pfizer Ltd.; M. Thakur, MD, Pfizer Ltd.; H.E. Jones, RN, Pfizer Inc.; J. Woolcott, PhD, Pfizer Inc.; P.V. Santos Estrella, MD, Pfizer Inc.; C. Rolland, PhD, Envision Pharma Group; A. Gibofsky, MD, Weill Medical College; G. Citera, MD, Instituto de Rehabilitación Psicofísica de Buenos Aires; S. Sockalingam, MMed, University Malaya Medical Centre; L. Marshall, PhD, Pfizer Inc. Address correspondence to P. Emery, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Chapel Allerton Hospital, Leeds LS7 4SA, UK. E-mail: p.emery@leeds.ac.uk. Accepted for publication May 17, 2019.
Catherine Rolland
From the Leeds Institute of Rheumatic and Musculoskeletal Medicine, and Leeds National Institute for Health Research (NIHR) Biomedical Research Centre, The Leeds Teaching Hospitals Trust, Leeds, UK. The systematic literature review to support this manuscript was sponsored by Pfizer. PE declares consultancy fees from AbbVie, Bristol-Myers Squibb, Eli Lilly & Co., and Novartis. BV, PS, MT, HEJ, JW, PVSE, and LM are employees of Pfizer, or were employees of Pfizer when this study was conducted, and hold stock or stock options with Pfizer. AG holds stock in AbbVie, Amgen, Celgene, GSK, Johnson & Johnson, Pfizer, and Regeneron, and declares consultancy fees from AbbVie, Celgene, Merck & Co., and Pfizer, and has served on a speakers’ bureau for AbbVie, Celgene, Flexion, Merck & Co., Novartis, and Pfizer. CR is an employee of Envision Pharma Group and was a paid consultant to Pfizer in connection with the development of the systematic literature review. GC declares consultancy fees from Bristol-Myers Squibb and Pfizer. P. Emery, FMedSci, Leeds Institute of Rheumatic and Musculoskeletal Medicine, and Leeds NIHR Biomedical Research Centre, The Leeds Teaching Hospitals Trust; B. Vlahos, MBA, Pfizer Inc.; P. Szczypa, MD, Pfizer Ltd.; M. Thakur, MD, Pfizer Ltd.; H.E. Jones, RN, Pfizer Inc.; J. Woolcott, PhD, Pfizer Inc.; P.V. Santos Estrella, MD, Pfizer Inc.; C. Rolland, PhD, Envision Pharma Group; A. Gibofsky, MD, Weill Medical College; G. Citera, MD, Instituto de Rehabilitación Psicofísica de Buenos Aires; S. Sockalingam, MMed, University Malaya Medical Centre; L. Marshall, PhD, Pfizer Inc. Address correspondence to P. Emery, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Chapel Allerton Hospital, Leeds LS7 4SA, UK. E-mail: p.emery@leeds.ac.uk. Accepted for publication May 17, 2019.
Allan Gibofsky
From the Leeds Institute of Rheumatic and Musculoskeletal Medicine, and Leeds National Institute for Health Research (NIHR) Biomedical Research Centre, The Leeds Teaching Hospitals Trust, Leeds, UK. The systematic literature review to support this manuscript was sponsored by Pfizer. PE declares consultancy fees from AbbVie, Bristol-Myers Squibb, Eli Lilly & Co., and Novartis. BV, PS, MT, HEJ, JW, PVSE, and LM are employees of Pfizer, or were employees of Pfizer when this study was conducted, and hold stock or stock options with Pfizer. AG holds stock in AbbVie, Amgen, Celgene, GSK, Johnson & Johnson, Pfizer, and Regeneron, and declares consultancy fees from AbbVie, Celgene, Merck & Co., and Pfizer, and has served on a speakers’ bureau for AbbVie, Celgene, Flexion, Merck & Co., Novartis, and Pfizer. CR is an employee of Envision Pharma Group and was a paid consultant to Pfizer in connection with the development of the systematic literature review. GC declares consultancy fees from Bristol-Myers Squibb and Pfizer. P. Emery, FMedSci, Leeds Institute of Rheumatic and Musculoskeletal Medicine, and Leeds NIHR Biomedical Research Centre, The Leeds Teaching Hospitals Trust; B. Vlahos, MBA, Pfizer Inc.; P. Szczypa, MD, Pfizer Ltd.; M. Thakur, MD, Pfizer Ltd.; H.E. Jones, RN, Pfizer Inc.; J. Woolcott, PhD, Pfizer Inc.; P.V. Santos Estrella, MD, Pfizer Inc.; C. Rolland, PhD, Envision Pharma Group; A. Gibofsky, MD, Weill Medical College; G. Citera, MD, Instituto de Rehabilitación Psicofísica de Buenos Aires; S. Sockalingam, MMed, University Malaya Medical Centre; L. Marshall, PhD, Pfizer Inc. Address correspondence to P. Emery, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Chapel Allerton Hospital, Leeds LS7 4SA, UK. E-mail: p.emery@leeds.ac.uk. Accepted for publication May 17, 2019.
Gustavo Citera
From the Leeds Institute of Rheumatic and Musculoskeletal Medicine, and Leeds National Institute for Health Research (NIHR) Biomedical Research Centre, The Leeds Teaching Hospitals Trust, Leeds, UK. The systematic literature review to support this manuscript was sponsored by Pfizer. PE declares consultancy fees from AbbVie, Bristol-Myers Squibb, Eli Lilly & Co., and Novartis. BV, PS, MT, HEJ, JW, PVSE, and LM are employees of Pfizer, or were employees of Pfizer when this study was conducted, and hold stock or stock options with Pfizer. AG holds stock in AbbVie, Amgen, Celgene, GSK, Johnson & Johnson, Pfizer, and Regeneron, and declares consultancy fees from AbbVie, Celgene, Merck & Co., and Pfizer, and has served on a speakers’ bureau for AbbVie, Celgene, Flexion, Merck & Co., Novartis, and Pfizer. CR is an employee of Envision Pharma Group and was a paid consultant to Pfizer in connection with the development of the systematic literature review. GC declares consultancy fees from Bristol-Myers Squibb and Pfizer. P. Emery, FMedSci, Leeds Institute of Rheumatic and Musculoskeletal Medicine, and Leeds NIHR Biomedical Research Centre, The Leeds Teaching Hospitals Trust; B. Vlahos, MBA, Pfizer Inc.; P. Szczypa, MD, Pfizer Ltd.; M. Thakur, MD, Pfizer Ltd.; H.E. Jones, RN, Pfizer Inc.; J. Woolcott, PhD, Pfizer Inc.; P.V. Santos Estrella, MD, Pfizer Inc.; C. Rolland, PhD, Envision Pharma Group; A. Gibofsky, MD, Weill Medical College; G. Citera, MD, Instituto de Rehabilitación Psicofísica de Buenos Aires; S. Sockalingam, MMed, University Malaya Medical Centre; L. Marshall, PhD, Pfizer Inc. Address correspondence to P. Emery, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Chapel Allerton Hospital, Leeds LS7 4SA, UK. E-mail: p.emery@leeds.ac.uk. Accepted for publication May 17, 2019.
Sargunan Sockalingam
From the Leeds Institute of Rheumatic and Musculoskeletal Medicine, and Leeds National Institute for Health Research (NIHR) Biomedical Research Centre, The Leeds Teaching Hospitals Trust, Leeds, UK. The systematic literature review to support this manuscript was sponsored by Pfizer. PE declares consultancy fees from AbbVie, Bristol-Myers Squibb, Eli Lilly & Co., and Novartis. BV, PS, MT, HEJ, JW, PVSE, and LM are employees of Pfizer, or were employees of Pfizer when this study was conducted, and hold stock or stock options with Pfizer. AG holds stock in AbbVie, Amgen, Celgene, GSK, Johnson & Johnson, Pfizer, and Regeneron, and declares consultancy fees from AbbVie, Celgene, Merck & Co., and Pfizer, and has served on a speakers’ bureau for AbbVie, Celgene, Flexion, Merck & Co., Novartis, and Pfizer. CR is an employee of Envision Pharma Group and was a paid consultant to Pfizer in connection with the development of the systematic literature review. GC declares consultancy fees from Bristol-Myers Squibb and Pfizer. P. Emery, FMedSci, Leeds Institute of Rheumatic and Musculoskeletal Medicine, and Leeds NIHR Biomedical Research Centre, The Leeds Teaching Hospitals Trust; B. Vlahos, MBA, Pfizer Inc.; P. Szczypa, MD, Pfizer Ltd.; M. Thakur, MD, Pfizer Ltd.; H.E. Jones, RN, Pfizer Inc.; J. Woolcott, PhD, Pfizer Inc.; P.V. Santos Estrella, MD, Pfizer Inc.; C. Rolland, PhD, Envision Pharma Group; A. Gibofsky, MD, Weill Medical College; G. Citera, MD, Instituto de Rehabilitación Psicofísica de Buenos Aires; S. Sockalingam, MMed, University Malaya Medical Centre; L. Marshall, PhD, Pfizer Inc. Address correspondence to P. Emery, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Chapel Allerton Hospital, Leeds LS7 4SA, UK. E-mail: p.emery@leeds.ac.uk. Accepted for publication May 17, 2019.
Lisa Marshall
From the Leeds Institute of Rheumatic and Musculoskeletal Medicine, and Leeds National Institute for Health Research (NIHR) Biomedical Research Centre, The Leeds Teaching Hospitals Trust, Leeds, UK. The systematic literature review to support this manuscript was sponsored by Pfizer. PE declares consultancy fees from AbbVie, Bristol-Myers Squibb, Eli Lilly & Co., and Novartis. BV, PS, MT, HEJ, JW, PVSE, and LM are employees of Pfizer, or were employees of Pfizer when this study was conducted, and hold stock or stock options with Pfizer. AG holds stock in AbbVie, Amgen, Celgene, GSK, Johnson & Johnson, Pfizer, and Regeneron, and declares consultancy fees from AbbVie, Celgene, Merck & Co., and Pfizer, and has served on a speakers’ bureau for AbbVie, Celgene, Flexion, Merck & Co., Novartis, and Pfizer. CR is an employee of Envision Pharma Group and was a paid consultant to Pfizer in connection with the development of the systematic literature review. GC declares consultancy fees from Bristol-Myers Squibb and Pfizer. P. Emery, FMedSci, Leeds Institute of Rheumatic and Musculoskeletal Medicine, and Leeds NIHR Biomedical Research Centre, The Leeds Teaching Hospitals Trust; B. Vlahos, MBA, Pfizer Inc.; P. Szczypa, MD, Pfizer Ltd.; M. Thakur, MD, Pfizer Ltd.; H.E. Jones, RN, Pfizer Inc.; J. Woolcott, PhD, Pfizer Inc.; P.V. Santos Estrella, MD, Pfizer Inc.; C. Rolland, PhD, Envision Pharma Group; A. Gibofsky, MD, Weill Medical College; G. Citera, MD, Instituto de Rehabilitación Psicofísica de Buenos Aires; S. Sockalingam, MMed, University Malaya Medical Centre; L. Marshall, PhD, Pfizer Inc. Address correspondence to P. Emery, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Chapel Allerton Hospital, Leeds LS7 4SA, UK. E-mail: p.emery@leeds.ac.uk. Accepted for publication May 17, 2019.
In this issue
The Journal of Rheumatology
Vol. 51, Issue 3
1 Mar 2024
Longterm Drug Survival of Tumor Necrosis Factor Inhibitors in Patients with Rheumatoid Arthritis
Paul Emery, Bonnie Vlahos, Piotr Szczypa, Mazhar Thakur, Heather E. Jones, John Woolcott, Paul V. Santos Estrella, Catherine Rolland, Allan Gibofsky, Gustavo Citera, Sargunan Sockalingam, Lisa Marshall
The Journal of Rheumatology Jun 2019, jrheum.181398; DOI: 10.3899/jrheum.181398
Longterm Drug Survival of Tumor Necrosis Factor Inhibitors in Patients with Rheumatoid Arthritis
Paul Emery, Bonnie Vlahos, Piotr Szczypa, Mazhar Thakur, Heather E. Jones, John Woolcott, Paul V. Santos Estrella, Catherine Rolland, Allan Gibofsky, Gustavo Citera, Sargunan Sockalingam, Lisa Marshall
The Journal of Rheumatology Jun 2019, jrheum.181398; DOI: 10.3899/jrheum.181398